CClinicalTrials.gg
CompletedNCT01986205HYBOBI2Updated Aug 4, 2022

Hyperbaric Oxygen for Traumatic and Non-traumatic Brain Injury

A Phase 2 interventional study of Hyperbaric Oxygen and Minimal pressure air in Brain Injury, Chronic, sponsored by Lindell Weaver. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-08-04.

Sponsored by Lindell Weaver · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2022, 4 years 4 months ago, and no results have been posted to the registry.
Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to examine whether 40 hyperbaric oxygen sessions has effect on long-term symptoms after brain injury. This study will enroll 90 individuals with persistent problems 6 months to 10 years after a brain injury. These individuals will be randomized to receive either oxygen or air in a pressurized hyperbaric chamber. Participants will receive 40 daily hyperbaric chamber sessions.

Participants will have a series of tests and questionnaires before they begin their chamber sessions, after they complete 40 sessions, and 6 months after they joined the study. These tests include computer-based and pencil-and-paper questionnaires and thinking tests, brain imaging, a neurological examination, and an eye exam. Participants will also be asked to provide blood for future research.

After the 6-month tests are complete, all participants will receive 40 hyperbaric oxygen sessions, then undergo the same tests at 9 months and 12 months.

Read the detailed description

This is a single center, randomized, double-blind study with a subsequent open-label intervention period to explore whether a course of hyperbaric oxygen can ameliorate persistent symptoms after brain injury. In this study, adult men and women with persistent symptoms 6 months to 10 years after injury will be randomized to receive 40 hyperbaric oxygen sessions (100% oxygen at 1.5 atmospheres absolute, 60 minutes door-to-door) or sham chamber sessions (room air chamber excursion at near-ambient pressure, 60 minutes door-to-door). Chamber sessions will be provided Monday through Friday, excluding holidays, and participants will have up to 12 weeks to complete their 40 sessions.

Participants will be evaluated before the chamber sessions, at 13 weeks, and at 6 months. Assessments include self-administered questionnaires, neuropsychological function, a brief neurological examination, electroencephalography, visual function tests, and a neuro-optometry evaluation. These outcome tools will measure symptoms and deficit at the time of enrollment and subsequent evaluations, and provide insight into whether hyperbaric oxygen can play a role in recovery from brain injury.

Once the participants have completed their 6 month evaluations, they will enter an open intervention group, receiving 40 hyperbaric sessions at 1.5 atmospheres absolute for 60 minutes. Participants will have up to 12 weeks to complete these sessions. Participants will be evaluated after the second set of chamber sessions (at 9 months and again at 12 months). Individuals will then be assessed annually until study closure (12-month follow-up of the last enrolled participant).

Participants will be asked to provide blood for long-term storage of serum, plasma, and DNA for future investigations, including apolipoprotein E genotype.

02

Conditions studied

  • Brain Injury, Chronic

Keywords

  • Concussion
  • Traumatic brain injury
  • Hyperbaric oxygenation
  • Post-concussion symptoms
  • Headache
  • Carbon monoxide
03

In context

Brain Injuries

2,113 studies on the registry are indexed under Brain Injuries; 385 are open to participants now.

This study's enrollment of 49 is close to the median of 48 across 1,331 interventional studies indexed under Brain Injuries.

Browse Brain Injuries studies →

Lead sponsor

Lindell Weaver is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults, age 18-70 years, both men and women
  • Able to speak and read English as primary language
  • Able and willing to provide written informed consent for study participation.
  • Able and willing to complete outcome assessments and provide blood and urine samples as required by the study protocol.
  • Able to tolerate the chamber environment and hood placement and to equalize middle ear pressure.
  • Past history of at least one brain injury with persistent symptoms that meets all of the following criteria:

    • Brain injury of non-stroke etiology that occurred at least 6 months but no more than 10 years prior to enrollment.
    • At least 3 of the following persistent symptoms from the injury: headaches, dizziness or balance problems, blurred vision, tiredness/fatigue or sleep problems, seizures, remembering things or solving problems, managing stress or emotional upsets, controlling temper/irritability, depression, anxiety, post-traumatic stress, or ringing in the ears.
  • Normal thyroid stimulating hormone and hematocrit value greater than 35% within the previous 6 months.

Exclusion criteria

Exclusion Criteria:

  • Contraindications to hyperbaric oxygen

    • Insulin-dependent diabetes mellitus, or diabetes mellitus that is not reasonably controlled.
    • Uncontrolled seizure disorder (participants must be on therapy and seizure-free for at least 6 months).
    • Claustrophobia precluding chamber or hood tolerance.
    • Implanted devices not cleared for hyperbaric pressurization.
    • Pregnancy or plans to become pregnant during the study participation period. Women of childbearing potential will be asked to use an acceptable form of birth control during study participation.
    • Lung disease, such as emphysema, chronic bronchitis, asthma that is not well-controlled, or bullous lung disease that raises the risk for pulmonary barotrauma due to air trapping.
    • Active malignancy, previous malignancy (except basal cell carcinoma) in the last 5 years, or any prior treatment with bleomycin (Blenoxane). Prior treatment with doxorubicin (Adriamycin) is acceptable as long follow-up echocardiography is normal.
    • Chronic disease such as heart or renal failure would raise the participant's risk of adverse events during hyperbaric oxygen.
  • Confounds to the outcome assessments

    • Inability to speak English as their primary language (English fluency required because many of the outcomes are only in available in English)
    • Instability with walking requiring more than a cane for assistance
    • Alcohol abuse, by self-report, within the last year.
    • Lifetime history of illicit drug use, by self-report, except remote (greater than one year), non-habitual use of marijuana.
    • Failed urine drug screen during study participation.
    • Continued participation during the intervention period in sports activities where head injury is likely, such as contact football, boxing, mixed martial arts, etc.
    • Blind or deaf.
    • Major psychiatric disorder or degenerative mental disease (such as multiple sclerosis).
    • Prior therapeutic radiation to the central nervous system.
    • Personal history of any condition that pre-dates their brain injury that resulted in diminished capacity (such as chromosomal disorders) or that, in the opinion of the investigators, affects cognition to such a degree that the outcome assessments are invalidated (such as learning disability or attention deficit hyperactivity disorder requiring pharmaceutical therapy as an adult).
    • Any brain injury from stroke (ischemic or hemorrhagic)
    • Known untreated chronic or acute medical conditions, such as hypothyroidism, Cushing's disease, untreated hypertension, etc., that would confound the outcome assessments or inhibit compliance with the study protocol. If treated, these disorders would not be excluded.
    • Concomitant enrollment in any other drug/device clinical trial.
    • Prior hyperbaric oxygen for any reason within the last year.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Hyperbaric Oxygen

    100% oxygen at 1.5 atmospheres absolute for 60 minutes, 40 sessions

    Combination Product: Hyperbaric Oxygen

  • Placebo comparator
    Minimal pressure air

    Regular air at minimal pressurization for 60 minutes, 40 sessions

    Combination Product: Minimal pressure air

Interventions

  • Combination productHyperbaric Oxygen

    Hyperbaric oxygen (USP oxygen \>99%) delivered in a hyperbaric chamber pressurized to 1.5 atmospheres absolute.

    Also known as: HBO2, HBOT, HBO, Hyperbaric oxygen therapy

  • Combination productMinimal pressure air

    Room air delivered in a hyperbaric chamber with minimal pressurization.

    Also known as: Room air

06

What researchers measure

Primary outcomes

  1. Neurobehavioral Symptom Inventory

    Participant-reported symptom rating of post-concussive symptoms

    Time frame: 13 weeks

Secondary outcomes

  1. Neurobehavioral Symptom Inventory

    Participant-reported symptom rating of post-concussive symptoms

    Time frame: 6 months

  2. Incidence of myopia

    Myopic visual changes after chamber sessions

    Time frame: 13 weeks

07

Study locations

2 sites
  • Intermountain Medical Center
    Murray, Utah 84157, United States
  • Intermountain LDS Hospital
    Salt Lake City, Utah 84143, United States
08

References and documents

Publications

  • Churchill S, Weaver LK, Deru K, Russo AA, Handrahan D, Orrison WW Jr, Foley JF, Elwell HA. A prospective trial of hyperbaric oxygen for chronic sequelae after brain injury (HYBOBI). Undersea Hyperb Med. 2013 Mar-Apr;40(2):165-93. PubMed 23682548 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01986205
Lead sponsor
Lindell Weaver
Responsible party
Lindell Weaver (Medical Director, Hyperbaric Medicine, Intermountain Health Care, Inc.) — Sponsor-investigator
First posted
Nov 18, 2013
Start date
Sep 6, 2017
Primary completion
May 31, 2022
Completion
May 31, 2022
Last update
Aug 4, 2022

Study contacts

Lindell K. Weaver, MD
principal investigator · Intermountain Health Care, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion